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Youngsters are increasingly using 3,4 methylenedioxymethamphetamine, known as ecstasy, because it is wrongly
believed that it does not induce harm. However, there are many reports of adverse effects, including acute intoxication,
abuse potential, and possible neurotoxic effects. Therefore, health care providers need to promptly recognize the symptoms
of systemic intoxication in order to initiate early treatment. The drug is used by the oral route for long hours during crowded
dance parties. Acutely, ecstasy increases the release of serotonin and decreases its reuptake, leading to hypertension,
hyperthermia, trismus, and vomiting. There is debate on whether recreational doses of ecstasy cause permanent damage to
human serotonergic neurons. Ecstasy users showed a high risk of developing psychopathological disturbances. The prolonged
use of ecstasy might induce dependence, characterized by tolerance and hangover. Acute ecstasy intoxication needs
emergency-type treatment to avoid the dose-dependent increase in adverse reactions and in severity of complications.
There are no specific antidotes to be used during acute intoxication. Supportive measures and medical treatment for each
one of the complications should be implemented, keeping in mind that symptoms originate mainly from the central nervous
system and the cardiovascular system.
DESCRIPTORS: 3,4 methylenedioxymethamphetamine. Adverse effects. Substance-related disorders. Cognition.
Hyperthermia.
In 2001, an estimated 8.1 million
(3.6%) Americans aged 12 or older had
tried ecstasy at least once in their life-
times. This is more than the estimated
6.5 million (2.9 %) lifetime users in
20001. The Brazilian National House-
hold Survey on Psychoactive Drug Use
detected that 0.6% of respondents
aged 12 or older used ecstasy or other
hallucinogens, meaning that 295,000
Brazilians used this group of drugs at
least once in their lifetimes2.
Ecstasy or 3,4 methylene-
dioxymethamphetamine (MDMA) is a
synthetic amphetamine3-5, the wide-
spread use of which since the 1980s
might be related to the exaggerated
declaration of possible therapeutic ef-
fects by some authors6. This drug is
also known as XTC, E, Adam, MDM
or “ drug of love”7. The behavioral ef-
fects of increased self-confidence, un-
derstanding and empathy, and an in-
creased sensation of proximity and in-
timacy with other people are described
mainly in uncontrolled studies. Com-
munication and personal relationship
skills were also described to improve.
Euphoria and increased emotional and
physical energy are presumed to occur
with this psychostimulant8-11. Since the
subjective effects of MDMA in hu-
mans are not the same as those pro-
duced by LSD and because the drug
does not have a similar structure or
pharmacological activity to hallucino-
gens or psychedelic drugs, the term
“entactogens” meaning “entering in
contact with yourself”10,11 was pro-
posed to define a new pharmacologi-
cal class. Also, a never-proven sexual
enhancement action was cited by ex-
perimental consumers12,13. However,
ecstasy does not increase the excite-
ment or the sexual desire in most of the
users, and orgasms may be delayed due
to higher awareness of sensory input,
especially in men; it cannot be classi-
fied as an agent to treat sexual
dysfuctions12. Ecstasy can be more
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easily classified as a psychostimulant,
since it has chemical and action simi-
larities with cocaine and ampheta-
mines. According to the American Psy-
chiatric Association, ecstasy may be
classified as a hallucinogen, due to its
potential to occasionally induce hal-
lucinations and “flashbacks” if used in
extremely high doses14. Certainly, in
the coming years, a better understand-
ing of the drug’s effects will allow its
accurate classification.
Nowadays, MDMA is becoming the
center of discussion in both lay and
scientific press for its abuse potential
and possible neurotoxic effects. In the
beginning of the 1990s, it was banned
as a therapeutic drug by the World
Health Organization15. Ecstasy was in-
troduced in Brazil around 1994. Since
1997, ecstasy has been a topic of ques-
tioning for drug hot lines in Brazil16. In
Brazil, ecstasy is sold at all-night dance
parties attended by hundreds of thou-
sands of youngsters where loud techno
music is played, and bright and pulsat-
ing lights fill the environment. There is
evidence that until now, the use of ec-
stasy has been limited to middle-class
or upper-middle-class individuals in
Brazil, so that most people, including
health care professionals, are unfamil-
iar with the drug. However, ecstasy may
be becoming more popular in Latin
America, following the pattern seen in
North America and Europe. The fact
that ecstasy is sold as a pill and is thus
extremely easy to use is a possible con-
tributing factor to the drug’s popular-
ity17. In a recent survey in the city of
São Paulo, most ecstasy users were
shown to have attended universities
and use dance party events and the
Internet for entertainment. These indi-
viduals are equally distributed in het-
erosexual and homosexual groups, with
respect to sexual orientation, and most
of them use piercing and tattoos. Ac-
cording to these individuals, the ex-
perimental use of the drug occurred due
to its easy acquisition18.
In Northern Hemisphere countries,
adolescents with a polydrug-use pat-
tern also consume ecstasy. The sub-
stance is introduced later in a drug-use
sequence of legal and illegal sub-
stances. The pattern of ecstasy use dif-
fers from the use of amphetamines; it
is strongly associated with subcultural
music preferences and house-party go-
ing and weakly associated with smok-
ing and conduct problems19. Its use is
increasing in college students who also
use marijuana, alcohol, have multiple
sex partners, and spend more time so-
cializing than studying20. Gay/bi-
sexual men who are MDMA users
(13% of the group) were found to be
younger, less educated, to have had
more male partners, more one night
stands with men, to have unprotected
anal sex with males, to have more gay/
bisexual friends, and to have higher
levels of gay community participation
and affiliation than nonusers21.
Ecstasy has a reputation of being
a safe drug; however, there are many
reports of adverse reactions associated
with the drug, as described in other re-
views3,22,16,23,24. The increasing popular-
ity of ecstasy among youngsters
prompts the need for health care pro-
viders to quickly recognize the symp-
toms of severe systemic intoxication
in order to initiate early treatment, with
rehydration and cooling in cases of
hyperthermia, for seizures, cardiac ar-
rhythmia, and for metabolic and elec-
trolyte abnormalities. The need for
more information on ecstasy seems to
be growing due to its increased use,
detectable by the higher number of re-
ports of intoxication with ecstasy.
Therefore, the objective of this review
is to give a recent picture of the clini-
cal effects of the drug and the conse-
quences of drug use. We also reviewed
some preclinical studies performed
with experimental animals to elucidate
clinical problem mechanisms and dis-
cuss future prevention methods for
long-term adverse outcomes of ecstasy.
PATTERNS  OF  ECSTASY  USE
Ecstasy was synthesized and pat-
ented in Germany by Merck in 1914
for appetite control. However, it was
never released in the market22, and the
scientific community ignored it until
1970. At that time, ecstasy was re-
ported to produce “a controllable state
of alteration of conscience with sen-
sual and emotional harmony”, suggest-
ing that it could be used as an
adjuvant in psychotherapy8,9,25. In the
beginning of the 1980s, MDMA be-
came popular as a recreational drug26,27.
Around 1985, the USA Drug Enforce-
ment Administration (DEA) restricted
the therapeutic use of MDMA, placing
it on the list of forbidden substances
and without clinical use due to its fre-
quent abuse and to central nervous
system serotonergic degenera-
tion22,24,28,29. Due to the expansion of
the illegal drug market and the belief
that the use of ecstasy for recreational
purpose is safe, the number of cases of
toxicity related to ecstasy or to a mix-
ture of substances sold as ecstasy has
been increasing6. However, several sci-
entific reports confirm that ecstasy is
potentially fatal, and therefore, precau-
tions should be taken to avoid the be-
ginning of its use by children and ado-
lescents30,31.
Ecstasy is used orally and is sold as
tablets or capsules of several colors,
shapes, and sizes, containing from 50
to 150 mg of the drug. Sometimes it is
sold as a powdered substance to be
mixed with beverages6,32,33. There are
descriptions of rectal use and intrana-
sal use of the powdered MDMA34. The
street preparations are up to 90% pure34
and may also contain MDA, caffeine,
LSD, amphetamine, methamphetamine,
mixture of amphetamines, paracetamol,
or ketamine and other nonidentified
substances34,35. Therefore, since quality
control does not exist in the illicit drug
market, consumers are subject to addi-
tional risk. When the typical recrea-
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tional doses are used, MDMA is not
frankly hallucinogenic24,26. Changes in
perception and hallucinations occur in
big gatherings. The typical dose for
recreational purpose is 70 to 150 mg,
corresponding to 1 or 2 capsules or tab-
lets. Dose supplements of 50 to 100 mg
may be taken every 30 minutes18,24 due
to the expectation of increasing the in-
tensity of the experience34. In Brazil,
most individuals use up to 1 tablet per
night chronically, however a few of
them reported the use of more than 3
tablets per night18. The recreational use
of ecstasy is done more frequently dur-
ing weekends in dance clubs or parties
where crowds dance vigorously. Raves,
meaning delirium or fury, are all-night
dance parties attended by a large
number of people, sometimes exceed-
ing 20,000. The rave scene is interna-
tional and may be accompanied by
clandestine activities, hypnotic elec-
tronic music, and the liberal use of
drugs (marijuana, alcohol, cocaine,
heroin, gamma-hydroxybutyrate, and
ketamine) in addition to ecstasy20,21,36-
39
. Therefore, raves accumulate condi-
tions that induce or increase the number
of toxic or lethal cases induced by ec-
stasy because they are crowded, very
noisy, and may develop high environ-
mental temperatures23,33. Most of the
patients with serious ecstasy intoxica-
tion present dehydration, fainting, or
convulsions, and they frequently need
treatment at hospital emergency depart-
ments37. Because of that, in some places
where youngsters go to get the drug and
to party, the “drug agencies” are spe-
cially prepared to assist ecstasy users
and to minimize the adverse effects ac-
companying drug use16.
The recreational use of ecstasy be-
gan among North American students,
and its consumption has been increas-
ing in Spain, Italy, England, and in
countries of Latin America6,16,40. It is
used in environments where the con-
sumption of cocaine and alcohol is
also prevalent34,41. Students, house-
wives, merchants, health professionals,
and writers, as well as unemployed in-
dividuals have been motivated by cu-
riosity to start ecstasy use34. The in-
crease of the recreational use of
MDMA by youth is well documented;
however, reports about ecstasy effects
in children do not exist30. Accurate es-
timates of the prevalence and inci-
dence of ecstasy use are still under
scrutiny in several countries.
The pattern of ecstasy use is rather
uncommon when compared to the use
pattern of other substances. The recrea-
tional use is frequently spaced by 2 to
3 weeks. One of the reasons for this
pattern might be that the pleasant ef-
fects of the drug seem to decrease at
the same time as the “negative effects
“ increase if 5 or more doses of the
drug are used frequently. In the 1980s,
MDMA was used less than twice per
month, and most individuals had lower
than 10 drug experiences in their en-
tire lifetime34. More recently, higher
frequency of drug use is already being
described with individual cases of
daily and intense use of ecstasy18,24.
This can be seen in the Brazilian popu-
lation, since half of the ecstasy users
in São Paulo report the use of ecstasy
on 5 to 50 different occasions, while
around one-third of the interviewees
reported the use of ecstasy on 50 to
500 occasions18 .
TOXICOKINETICS
There is incomplete knowledge
about the pharmacological properties
of MDMA in humans, since the stud-
ies are difficult to perform because of
ethical issues22,42. Only case reports43
and small randomized double-blind
clinical studies42 among healthy peo-
ple using small to moderate doses of
ecstasy are reported. The psychosti-
mulant effects of MDMA are observed
20 to 60 minutes after the ingestion of
moderate doses of ecstasy, 75 to 100
mg and last from 2 to 4 hours3,26. Peak
ecstasy plasma levels occur 2 hours af-
ter oral administration, and residual
levels of 0.005 mg/L are found after 24
hours from the last dose42,43. The oral
dose of 50 mg of ecstasy produces a
maximum plasma level of 0.11 mg/L,
75 mg produces a level of 0.13 mg/L,
and 125 mg produces a level of 0.23
mg/L. There is lack of data on the per-
cent of oral absorption of MDMA22.
The area under the curve (AUC) of
plasma concentrations of ecstasy is
0.99 mg/L after 50 mg and may reach
2.2 mg/L after 125 mg. The consump-
tion of several capsules of ecstasy
causes drug plasma levels up to around
7.72 mg/L. More than 40 tablets of ec-
stasy are described to have been used
in some of the overdose cases and pro-
duced plasma levels 6 to 70 times
higher than this37. The AUC describes
the concentration of the drug in
plasma as a function of time and sug-
gests that MDMA has a non-linear
pharmacokinetic profile; consumption
of elevated doses of the substance may
produce disproportional elevation of
plasma levels of ecstasy5,42.
MDMA or ecstasy is widely distrib-
uted in the mammalian organism, eas-
ily crossing membranes and the blood-
brain barrier. The amount of drug bind-
ing to plasma proteins is unknown22.
Its clearance depends partially on liver
metabolism, 3% to 7% become the ac-
tive substance MDA, and 28% is
biotransformed to other metabolites.
Around 65% of the dose is eliminated
without being metabolized through
the kidneys42,43. As with all amines, uri-
nary excretion depends on the urinary
pH. Acidification of urine increases
drug elimination, which could be ap-
plied to speed drug clearance during
intoxication22. However, acidification
is rarely recommended due to the risk
of worsening nephrotoxicity by my-
oglobinuria44.
The plasma half-life of ecstasy is
7.6 hours. This information is very rel-
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evant when treating intoxication, be-
cause 6 to 8 half-lives are necessary to
complete depuration of the drug;
therefore, about 48 hours would be
necessary for the complete elimination
of ecstasy. It can also be foreseen that
for a plasma level of 8 mg/L, which is
considered to be the severe intoxica-
tion level, about 24 hours would be
necessary to decrease to a plasma level
lower than 1 mg/L, which produces
much less clinical effects. Therefore,
this would be the estimated time of in-
tensive care needed by intoxicated pa-
tients who used a few ecstasy capsules.
However, this time would be longer
when a higher number of tablets are
consumed, since drug depuration is
not linear.
ACUTE  AND  CHRONIC
BEHAVIORAL  EFFECTS
The neuropsychiatric effects in-
duced by ecstasy may be classified
into different categories. The acute
subjective effects are altered perception
of time and changes in visual percep-
tion, increased self-confidence, under-
standing and empathy with decreased
defensiveness and aggression, and in-
creased social interactions. Communi-
cation and personal relationship skills
were also described to improve. In-
creased emotional and physical “en-
ergy” is presumed to occur with this
psychostimulant; however, there is de-
creased ability and less desire to per-
form mental or physical tasks. Eupho-
ria, decreased sleep, appetite, fatigue,
depressed mood, and decreased anxi-
ety are described as short-term ef-
fects10,11,15,25,28. Other central nervous
system effects range from euphoria,
central nervous stimulation, and feel-
ings of closeness to mild hallucina-
tions, impairment of cognition and co-
ordination, and more serious reactions
like agitation, disturbed and bizarre
behavior, and possibly psychosis.
When the typical recreational doses
are used, MDMA is not frankly hallu-
cinogenic24,26. Changes in perception
and hallucinations occur in cases of
intoxication with higher doses of 300
mg or more34. These hallucinations are
similar to those produced by mesca-
line. Initially, visual hallucinations are
in black and white and later become
colorful. Modification of body percep-
tion with sensation of depersonaliza-
tion, confusion, illusions, and sensa-
tion of lightness or flotation may oc-
cur34. In addition to these behavioral
effects, symptoms include trismus,
bruxism, nystagmus, motor tics, rest-
lessness, headaches, and anxiety45. The
most frequently perceived adverse ef-
fects are decreased desire to execute
physical and mental tasks (70%), de-
creased appetite (65%), and trismus
(50%)15. It must be assumed that the
risk of being involved in traffic acci-
dents during MDMA use is increased.
The prevalence of detectable MDMA
blood levels indicate an increased risk
of reckless driving comparable to that
observed after the use of ampheta-
mine46.
Psychopathologies associated with
the use of MDMA are classified as
acute, when occurring in the first 24
hours after drug use, subacute when
occurring 24 hours to 1 month after
drug ingestion, and chronic if they oc-
cur after a month of drug use24,45. The
most frequent acute complications in-
clude anxiety, insomnia, flashbacks,
panic attacks, and psychotic
spells48,49,50. Those who have acute
paranoid psychotic reactions after tak-
ing MDMA may become violent and
are likely to react in the same way
when taking the drug again51. The su-
bacute complications include depres-
sion, dizziness, anxiety, and irritabil-
ity. MDMA consumers are found to be
at high risk of developing psycho-
pathological disturbances, mainly
flashbacks, depression, psychotic dis-
orders, cognitive disturbances, bulimic
episodes, impulse control disorders,
panic disorders, and social pho-
bia48,49,52. The cases of paranoid psy-
chosis after abuse of MDMA show that
there is an organic disorder secondary
to the neurotoxic effect of MDMA
rather than a temporary functional
mental disorder53. Depression in ec-
stasy patients could be related to
serotonergic function as measured
through PET scans54. In fact, weekend
use of MDMA may lead to mid-week
depressed mood, and the possible
mechanism underlying the behavioral
changes includes temporary depletion
of serotonin, due to serotonergic
neurotoxity55.
For 10 years, ecstasy has been rec-
ognized as inducing psychological
dependence after daily use of high
doses for prolonged time34. Physiologi-
cal dependence is not yet recognized
because “craving” or withdrawal syn-
drome was not described34. However,
based on the diagnostic criteria for
substance dependence by the Ameri-
can Psychiatric Association14, physi-
ological dependence by ecstasy should
be kept in mind. Actually, the pro-
longed use of ecstasy fulfills 4 depend-
ence criteria: it is used in larger doses
than the ones initially planned56; it is
used in spite of the knowledge of the
adverse effects, it produces a hangover
characterized by insomnia and fa-
tigue57; and it may induce tolerance48.
Tolerance to the psychoactive proper-
ties of MDMA develops rapidly, and
there are some individuals who use in-
creasing amounts of ecstasy to rein-
force the psychoactive effect18,48. In
some individuals, tolerance occurs to
some of the pleasant psychoactive ef-
fects of ecstasy but not to the physi-
cal effects, and the dose increase may
produce dysphoria26. In this group of
individuals, MDMA does not cause
dependence, and the use of very large
amounts of ecstasy, for a long period
is rare56. It is still necessary to define
which are the social, genetic, cultural,
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environmental, and hormonal factors
involved in these long-term individual
differences in ecstasy’s effects.
Perhaps the most disturbing aspect
of ecstasy effects is the risk of irrevers-
ible long-term neuropsychiatric ef-
fects33. MDMA is neurotoxic to sero-
tonergic neurons of different animal
species13, although there is debate on
whether recreational doses of ecstasy
may cause permanent damage to the
human brain33,56. In very recent publi-
cations, several authors presented evi-
dence that ecstasy might be neurotoxic
to humans58, 59, 60, 61, 62.
Cognitive performance may be af-
fected in drug-free recreational ecstasy
users, with reduced memory for new
information, impaired higher execu-
tive processing, and heightened impul-
sivity. Some ecstasy users also com-
plain of poor memory and/or concen-
tration difficulties, which they at-
tribute to the previous MDMA use.
This particular pattern of cognitive
decrement in humans is consistent
with the animal data showing seroto-
nergic damage following MDMA ad-
ministration, accompanied by impul-
sivity, higher cognitive impairment,
and memory deficit58.
In fact, ecstasy users showed a
broad pattern of statistically signifi-
cant, but clinically small, impairment
of memory as measured by direct re-
call and recognition and prolonged re-
action times that are accompanied by
changes in cortisol plasma levels.
Heavy users were more affected than
moderate users63. Significant impair-
ment was found on measures of verbal
memory and of delayed memory in ec-
stasy users. However performance was
similar across all parameters for visual
reaction time, auditory reaction time,
complex reaction time, visual memory,
and attention and concentration. There
is, therefore, evidence for long-term
neuropsychological sequelae associ-
ated with the use of ecstasy, particu-
larly with regard to delayed memory
ability59. Users processed information
as quickly as nonusers but less accu-
rately60. Ecstasy users were unimpaired
in simple tests of attention (alertness),
but performed worse than nonusers in
more complex attention tests, in
memory and learning tasks, and in
tasks reflecting aspects of general in-
telligence. Heavy ecstasy use and
combination with cannabis is associ-
ated with poorer performance by the
group of ecstasy users61.
There is ecstasy-related 5-HT neu-
ral injury associated with the func-
tional sequelae of ecstasy users de-
scribed above. In particular, ecstasy
users have selective decrements in cer-
ebrospinal fluid 5-hydroxyindo-
leacetic acid and a decreased number
of brain serotonin transporters, similar
to nonhuman primates with docu-
mented MDMA-induced neurotoxic-
ity62. Therefore, the neurochemical
data provide evidence that MDMA is
neurotoxic to brain serotonin neurons
in humans, and the behavioral data
suggests that brain serotonin injury is
associated with subtle, but significant,
cognitive deficits64.
MECHANISMS  OF  TOXICITY
 Probably, a sole mechanism of ac-
tion is insufficient to explain all ef-
fects induced by ecstasy. Due to its
complex activity spectrum, its effects
on human behavior can be related to
several neurochemical processes in-
volving serotonin, dopamine, and
norepinephrine8,10, similarly to what is
seen with other amphetamines13. How-
ever, serotonin plays the main role in
ecstasy effects22,65,66 .
There is an extensive body of data
demonstrating that ecstasy produces
toxic effects on brain serotonin neu-
rons in animals within the dose range
of recreational MDMA users due to
type 2 vesicular monoamine trans-
porter reduction67. The serotonin trans-
porter was significantly reduced in the
mesencephalon and the thalamus of
ecstasy users when compared with
drug-naive subjects. The distribution
volume ratios of the serotonin trans-
porter in former ecstasy users were very
similar to drug-naive subjects in all
brain regions, indicating protracted
but reversible lesions of the serotonin
transporter by PET68.
DIAGNOSIS  AND  TREATMENT
OF  ACUTE  INTOXICATION
WITH  ECSTASY
The well-known risks of adverse
reactions to ecstasy and their probable
mechanisms are summarized in table 1.
The intensity of the adverse events de-
pends on the dose, the frequency of
use, and on individual variation. It is
still not clear why some people use the
drug regularly without adverse out-
comes, while others present severe
toxic responses35. One of the possibili-
ties is that there might be differences
in effects at the first experience with
the drug or at a new acute episode fol-
lowing previous experiences with the
drug. These adverse events may be
acute, residual, or persistent. The acute
adverse effect may occur after the use
of low doses and may disappear in 24
hours. Overdose acute reactions occur
at indeterminate dosages, and have
been described to occur after the in-
take of 1 to 42 capsules of ecstasy. Re-
sidual effects have a hangover time
course, while persistent effects last for
up to 2 weeks. Gender differences in
effects are expected to be described,
because it is recognized that there are
more neurochemical effects of ecstasy
on females69, but epidemiological stud-
ies still do not provide evidence that
they are at higher risk than males when
using similar ecstasy doses.
Symptoms to be treated originate
mainly from the central nervous sys-
tem and the cardiovascular system.
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Death due to ecstasy overdose is asso-
ciated with arrhythmia or hyperten-
sion8,32,37 and may be associated with
acute bronchospasm, allergic reac-
tions, malignant hyperthermia, convul-
sions, disseminated intravascular co-
agulation, rhabdomyolysis, and acute
renal failure32,71,72 or hepatotoxicity73.
The estimated interval between drug
use and death varies between 2 and 60
hours6,30,73.
When treating an intoxicated pa-
tient, confirmation of the agent in-
volved should be sought. The analy-
sis of suspicious substances (powder
samples) or of corporal fluids (serum,
urinates, aspired gastric) can be accom-
plished by thin layer chromatography,
gaseous chromatography, ultraviolet
and infrared spectrophotometry or
flame ionization32,57. Based on the half-
life of the drug and time of renal elimi-
nation of ecstasy, the biological mate-
rial should be collected at least in the
first 72 hours from the beginning of
the intoxication disorder. Among the
general laboratory tests needed for pa-
tients intoxicated with ecstasy are
hematological assessment, because
MDMA is involved in the suppression
of bone marrow, and electrolytic as-
sessment to evaluate the degree of
dehydratation70.
Acute severe ecstasy intoxication
requires effective and quick treatment
to avoid the dose-dependent increase
in frequency of adverse reactions and
to prevent severe complications. It still
must be determined whether antagonist
agents acting at serotonergic, noradre-
nergic, or dopaminergic sites will have
beneficial effects if used to reverse the
drug effects. Currently, specific anti-
dotes against ecstasy are not avail-
able33, and similar treatment protocols
to the ones used for amphetamine or
cocaine intoxication are proposed. Ba-
sically, ventilatory and cardiovascular
support and appropriate treatment for
each one of the complications should
be implemented.
Ventilatory support to maintain the
airway and evaluation of body tem-
perature and decrease of body tempera-
ture if necessary are the first measures
to be implemented in ecstasy intoxi-
cation. Hyperthermia may be pre-
vented33. Heavy and frequent recrea-
tional users of MDMA may have im-
paired thermoregulation as demon-
strated in preclinical studies, and thus
may be at greater risk for acute adverse
response to MDMA in a hot, crowded
dance environment74. Thermoregula-
tion of individuals on ecstasy is labile
and much more dependent on environ-
mental conditions. Serotonergic an-
tagonists, such as ketanserin or methy-
sergide, or haloperidol may be needed
to stabilize body temperature; however,
neuroleptics must be used with extreme
care, because they may also cause
hyperthermia23. Selective or not selec-
tive reuptake inhibitors of serotonin,
such as tricyclic antidepressants,
fluoxetine, or citalopram are formally
contraindicated because they enhance
the effects of serotonin release and de-
crease the seizure threshold23.
Rehydration might be necessary
and should be done with caution due
to the risk of water intoxication. To
decrease muscular activity and for sei-
zure treatment and decrease of agita-
tion or anxiety, midazolam, diazepam,
or lorazepam should be given through
IV administration. The use of dantro-
lene as a muscular relaxant may be
necessary33,71. Clomethiazole is used in
England in the treatment of the acute
toxicity of the drug because of its ac-
tion at GABA receptors, with further
antagonism of the serotonergic syn-
Table 1 - Ecstasy behavioral effects after use of moderate doses or after repetitive intake and their probable neurotransmitter
mechanisms.
Patterns of use Acute doses Repetitive intake
Acute (low doses) effects tachycardia1, hypertension1, decreased appetite, trismus1,2, vomiting2, ataxia, nystagmus visual
bruxism1,2, nausea1, headaches1, insomnia1, tremor1, sudoresis1 allucination2, paresis/ paresthesia of
extremities, increased cold sensitivity
(may also occur in the first experience
with high dose)
Overdose reactions cardiac arrhythmias1, tachycardia1, palpitations1, hypertension screams3
and subsequent hypotension1, hyperthermia2,increased toxic hepatites4
muscular tonus, visual allucinations2, hepatotoxicity4, acute
renal failure, disseminated intravascular coagulation1,
rhabdomyolysis, death
Residual effects insomnia1, muscle aches, fatigue5, lightheadedness
Persistent effects fatigue5, depression5, nausea2, flashback2 panic and anxiety attacks2, persistent
insomnia1, psychosis3, loss of weight1,2,
irritability3
Noradrenergic effects 1; Serotonergic stimulation 2; Serotonergic deficiency 3; Idiosyncrasy 4; Noradrenergic/Serotonergic deficiency5.
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drome and antiseizure activity23. How-
ever, it is not available worldwide. Ha-
loperidol also attenuates ecstasy-in-
duced mania but has no reducing ef-
fect on other subjective changes or on
cardiovascular effects4.
Emesis is contraindicated, due to
the risk of inducing seizures in these
patients, but gastric lavage and admin-
istration of activated coal and a cathar-
tic may be indicated44. Chewing gum
counteracts jaw-clenching33. As already
pointed out, acidification of urine to
increase drug excretion is rarely recom-
mended due to the risk of worsening the
nephrotoxicity induced by myoglob-
inuria44. Hypertension and tachycardia
may be temporary in mild cases. For
moderate intoxications, sedatives or
oral nifedipine will be needed44. Other-
wise, patients may be treated with
vasodilators, phentolamine, or nitro-
prusside44. Arrhythmias are treated with
propranolol or esmolol; however, to
avoid paradoxical hypertension or coro-
nary insufficiency, labetalol might be
preferred. Hypotensive patients need
fluid reposition or vasoconstrictors44.
CONCLUSION
It is known that primary and sec-
ondary prevention of drug abuse is
fundamentally based on information.
Knowing about the dangerous effects
of a drug is the first step in avoiding
drug abuse. Recognizing and
promptly treating acute intoxication
prevents further damage. In spite of it
not being a new drug, the great major-
ity of health professionals do not know
the effects and possible complications
of ecstasy use. There is international
concern that ecstasy has the potential
to be the worst drug of the 21st cen-
tury, according to the Organization of
the United Nation. In Brazil, the Fed-
eral Council of Narcotics did not de-
tect the local production of the drug,
and the responsible organizations are
still determining the best approach for
combating its trafficking.
This review was sought with the in-
creasing use of ecstasy in mind. It might
be expected that with the increase in fre-
quency of ecstasy use worldwide, ecstasy
intoxication will become a frequent
emergency even in pediatric and inter-
nal medicine clinical practice. The re-
view on ecstasy intoxication treatment
discloses the need to find specific anti-
dotes instead of only having sympto-
matic treatment, which would be ex-
pected to enhance the quality of health
care provided to these patients.
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RESUMO
MARISTELA F e col. - Intoxicação
por êxtase: bases toxicológicas
para o tratamento. Rev. Hosp. Clín.
Fac. Med. S. Paulo 58(6):332-341,
2003.
Os jovens estão cada vez mais
usando o 3,4-metilenodioximetan-
fetamina, conhecido como êxtase, pois
acreditam que não causa danos. Entre-
tanto, existem muitos relatos de efei-
tos adversos, incluindo a intoxicação
aguda, abuso potencial e possíveis
efeitos neurotóxicos. Portanto, profis-
sionais da área da saúde necessitam re-
conhecer prontamente os sintomas da
intoxicação a fim de iniciar o tratamen-
to o mais breve possível. A droga é
usada via oral durante várias horas de
festas com danças. Agudamente, o êx-
tase aumenta a liberação do serotonina
e diminui sua recaptação, levando a
hipertensão, hipertermia, trismo e vô-
mitos. Há discussão se as doses recrea-
cionais causam danos permanentes aos
neurônios serotonérgicos em humanos.
Os usuários apresentam risco elevado
de desenvolver distúrbios psicopato-
lógicos, além disso, o uso prolongado
pode induzir a dependência, caracte-
rizada pela tolerância e ressaca. A in-
toxicação aguda necessita de trata-
mento de emergência, para se evitar re-
ações adversas e complicações graves.
Não há antidotos específicos para tra-
tar a intoxicação aguda. Medidas de
suporte e tratamento médico para cada
uma das complicações devem ser exe-
cutados, mantendo-se em mente que
os sintomas a serem tratados originam-
se principalmente do sistema nervoso
central e do sistema cardiovascular.
DESCRITORES: 3,4-metileno-
dioximetanfetamina. Efeitos adver-
sos. Desordens relacionadas a subs-
tância. Cognição. Hipertermia.
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